Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK-alloreactive bone marrow transplantation for high-risk AML
NL-OMON40743Phase 2Withdrawn
- Sponsor
- Maastricht University Medical Center+
- Start
- Oct 2014
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, thiotepa, busulfan, fludarabine, cyclosporine and 2 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Maastricht University Medical Center+. Primary endpoint: 1-year progression-free survival. Planned start Oct 2014; status: withdrawn.
02
Drugs
cyclophosphamidethiotepabusulfanfludarabinecyclosporine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON40743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40743.